Report Description Table of Contents Industry Report and Statistics (Facts & Figures) - Sales & Demand by Product & Technology The global renal denervation market will witness a robust CAGR of 40.7%, valued at $219.49 million in 2021, expected to appreciate and reach $4743.13 million by 2030, confirms Strategic Market Research. Hypertension is treated by minimally invasive treatment, which is catheter-based. The increasing prevalence of hypertension and its long-term conditions will drive market growth. Drivers - Increasing Patients Suffering from Hypertension Changes in lifestyles that led to an increase in hypertension cases and technological developments in this field, such as the innovation of micro-infusion, a renal denervation system, are the driving factors for the rise in global renal denervation devices market size. The growing usage of the endovascular catheter, radiofrequency ablation and the continuous rise in the number of cases of Congestive heart failure, left ventricular hypertrophy, atrial fibrillation, obstructive sleep apnea, insulin resistance/type 2 diabetes mellitus, treatment-resistant hypertension are increasing the demand of the market worldwide which is augmenting its growth significantly. Apart from that, the overall growth of the industry size and renal denervation treatment is expediting the growth of the entire industry. Restraints - Available Alternative, Sophisticated Technologies Micro-infusion is also one of the alternatives and improved technology for renal denervation systems. Thus, the main restraints of the market are the availability of other sophisticated technologies, strict regulatory body approvals, negative reimbursement, and a lack of trained healthcare workers. Renal Denervation Market Report Coverage Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 219.49 million The revenue forecast in 2030 USD 4743.13 million Growth rate CAGR of 40.7% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation Based on Technology and By region. Based on Technology Radiofrequency, Ultrasound, Micro-Infusion. By Region North America, Europe, Asia-Pacific, and LAMEA Country Scope US, Mexico, Canada, Germany, UK, France, China, Japan, India, etc. Company Usability Profiles Ablative Solutions, Inc, Abbott Laboratories, Johnson & Johnson, Cardiotonic Ltd, Boston Scientific Corporation, Medtronic plc, Mercator MedSystems, Inc, ReCor Medical, Inc, Renal Dynamics Limited, and Terumo corporation. Pricing and purchase options Customized buying options are available to meet your exact research needs. Opportunities - Growing Patient's Preference for The Use of Minimally Invasive Technologies A minimally invasive procedure is used to treat hypertension. Inside the renal artery wall, Ultrasound is sent to disrupt nerve impulse transmission and lower blood pressure by a device called ultrasound-based renal denervation devices. This process increases efficiency, thus paving the path for the future of the renal denervation market. Furthermore, with the growing usage of Medtronic Symplicity Spyral renal denervation, EnligHTN™, Vessix V2, Paradise™, Iberis™, and RENLANE, the growth is likely to propel in the upcoming times. Market Analysis Of Different Segments Covered in the Report Based on Technology Radiofrequency Ultrasound Micro-Infusion Regional Coverage Analysis Asia-Pacific China India Japan South Korea Taiwan Australia Rest of Asia-Pacific Europe Germany France Sweden Netherlands Switzerland Austria Belgium Denmark Ireland Finland United Kingdom Italy Rest of Europe LAMEA Brazil Argentina Chile Bahrain Egypt Iran Iraq Israel Kuwait Oman Qatar Saudi Arabia United Arab Emirates Turkey Rest of LAMEA North America United States Canada Mexico Rest of North America Segments Analysis & Insights Based on technology, according to the Report, Radiofrequency has the highest industry share and is expected to prolong in the future as well. Radiofrequency is a one-time procedure that suffices for at least two years to treat hypertension, thus increasing the market share. According to current industry trends, Europe is seeing maximum renal denervation market share based on region. At the same time, Asia Pacific is the fastest-growing market with the highest CAGR. Europe's highest market share is because of the CE mark approved by regulatory bodies. Renal Denervation Market Competitive Landscape Analysis Ablative Solutions, Inc Abbott Laboratories Johnson & Johnson Cardiotonic Ltd Boston Scientific Corporation Medtronic plc Mercator MedSystems, Inc ReCor Medical, Inc Renal Dynamics Limited Terumo Corporation Various Products that Key Market Players Develop Name of product Function Key player Symplicity Spyral RDN system Reduces blood pressure Medtronic plc SPYRAL HTN-OFF MED It is used to treat hypertension Brattea Vessix trial It is built in such a way that it delivers a modest dose of energy for disrupting the renal nerves surrounding the renal artery. Boston Scientific Corporation Paradise Renal Denervation Catheter It is used to treat Chronic Kidney Disease ReCor Medical, Inc Recent Developments On July 2022, a group of scientists from the United States developed an Ultrasound Based Renal-Denervation System for improvising the treatment process of Hypertension. A Radiance II Trial was conducted by the scientists under which this system showed excellent results by significantly reducing the ambulatory systolic BP within a time period of 2 months. Hence, it successfully received US FDA approval to be launched into the market. In October 2021, to treat uncontrolled hypertension in Europe, the ultrasound renal denervation system was launched by ReCor Medical Inc. In December 2020, for Paradise Ultrasound Renal Denervation System, a breakthrough device designation was announced by ReCor Medical in the RADIANCE-HTN TRIO Study. In March 2020, the first-ever clinical data from SPYRAL HTN-OFF MED Pivotal Trial was announced by Medtronic PLC. Frequently Asked Question About This Report Is renal denervation FDA approved? Two renal arteries denervation systems have the FDA approval Is renal denervation effective? Yes, it is effective in treating resistant hypertension What does renal denervation do? Renal Denervation treat resistant hypertension using a minimally invasive procedure Is renal denervation permanent? Yes, medication for Blood Pressure can be stopped. With respective regions, which is the largest market for Renal Denervation? According to current Renal Denervation Market Trends, based on region, Europe is seeing maximum renal denervation market share. Which are the key renal denervation devices market players across the globe? Ablative Solutions, Inc, Abbott Laboratories, Johnson & Johnson, Cardiotonic Ltd, Boston Scientific Corporation, Medtronic plc, Mercator MedSystems, Inc, ReCor Medical, Inc, Renal Dynamics Limited, Terumo corporation What are the renal denervation market growth? The global renal denervation market is expected to grow at a compound annual growth rate (CAGR) of 40.7 % from 2021 to 2030 to reach USD 4743.13 Million by 2030. How big is the renal denervation market? The global renal denervation market size was $ 219.49 Mn in 2021 and is predicted to reach $ 4743.13 Mn by 2030, with a CAGR of 40.7 %. . 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Renal Denervation Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 By Region, 2021 - 2030 (USD Million) 4.4 Technology Business Analysis 4.4.1 By Technology, 2021 - 2030 (USD Million) 4.5 Value Chain Analysis 4.6 Market Variable Analysis 4.6.1 Market Drivers Analysis 4.6.2 Market Restraints Analysis 4.7 Business Environment Analysis Tool 4.7.1 PEST analysis 4.7.2 Porter’s analysis 4.8 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Renal Denervation Manufacturing Sites, Area Served, Product Type 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Technology Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Radiofrequency 7.3.1. Radiofrequency Market, 2021 - 2030 (USD Million) 7.4.Ultrasound 7.4.1. Ultrasound Market, 2021 - 2030 (USD Million) 7.5 Micro-Infusion 7.5.1 Micro-Infusion Market, 2021 - 2030 (USD Million) 8. Global Market: Regional Outlook 8.1 North America 8.1.1. North America By Product Type, 2021 - 2030 (USD Million) 8.1.4. North America By Technology, 2021 - 2030 (USD Million) 8.1.5. North America By Country, 2021 - 2030 (USD Million) 8.1.4.1. U.S. 8.1.4.1.1. U.S. By Product Type, 2021 - 2030 (USD Million) 8.1.4.2. Canada 8.1.4.2.1. Canada By Product Type, 2021 - 2030 (USD Million) 8.1.4.2.2. Canada By Region, 2021 - 2030 (USD Million) 8.1.4.2.3. Canada By Technology, 2021 - 2030 (USD Million) 8.2. Europe 8.2.1. Europe By Product Type, 2021 - 2030 (USD Million) 8.2.2. Europe By Technology, 2021 - 2030 (USD Million) 8.2.5. Europe By Country, 2021 - 2030 (USD Million) 8.2.4.1 U.K. 8.2.4.1.1. U.K. By Product Type, 2021 - 2030 (USD Million) 8.2.4.1.2. U.K. By Technology, 2021 - 2030 (USD Million) 8.2.4.1.3. U.K. By Region, 2021 - 2030 (USD Million) 8.2.4.2. Germany 8.2.4.2.1. Germany By Product Type, 2021 - 2030 (USD Million) 8.2.4.2.2. Germany By Technology, 2021 - 2030 (USD Million) 8.2.4.2.3. Germany By Region, 2021 - 2030 (USD Million) 8.2.4.3. France 8.2.4.3.1. France By Product Type, 2021 - 2030 (USD Million) 8.2.4.3.2. France By Region, 2021 - 2030 (USD Million) 8.2.4.3.3. France By Technology, 2021 - 2030 (USD Million) 8.2.4.4. Rest of Europe 8.2.4.4.1. Rest of Europe By Product Type, 2021 - 2030 (USD Million) 8.2.4.4.2. Rest of Europe By Region, 2021 - 2030 (USD Million) 8.2.4.4.3. Rest of By Technology, 2021 - 2030 (USD Million) 8.3. Asia Pacific 8.3.1. Asia Pacific By Product Type, 2021 - 2030 (USD Million) 8.3.2. Asia Pacific By Technology, 2021 - 2030 (USD Million) 8.3.5. Asia Pacific By Country, 2021 - 2030 (USD Million) 8.3.4.1. China 8.3.4.1.1. China By Product Type, 2021 - 2030 (USD Million) 8.3.4.1.2. China By Region, 2021 - 2030 (USD Million) 8.3.4.1.3. China By Technology, 2021 - 2030 (USD Million) 8.3.4.2. India 8.3.4.2.1. India By Product Type, 2021 - 2030 (USD Million) 8.3.4.2.2. India By Region, 2021 - 2030 (USD Million) 8.3.4.2.3. India By Technology, 2021 - 2030 (USD Million) 8.3.4.3. Japan 8.3.4.3.1. Japan By Product Type, 2021 - 2030 (USD Million) 8.3.4.3.3. Japan By Technology, 2021 - 2030 (USD Million) 8.3.4.4. South Korea 8.3.4.4.1. South Korea By Product Type, 2021 - 2030 (USD Million) 8.3.4.4.3. South Korea By Technology, 2021 - 2030 (USD Million) 8.3.4.5. Rest of ASIA PACIFIC 8.3.4.5.1. Rest of ASIA PACIFIC By Product Type, 2021 - 2030 (USD Million) 8.3.4.5.3. Rest of ASIA PACIFIC By Technology, 2021 - 2030 (USD Million) 8.4. Latin America 8.4.1. Latin America By Product Type, 2021 - 2030 (USD Million) 8.4.3. Latin America By Technology, 2021 - 2030 (USD Million) 8.4.4. Latin America By Country, 2021 - 2030 (USD Million) 8.4.4.1. Brazil 8.4.4.1.1. Brazil By Product Type, 2021 - 2030 (USD Million) 8.4.4.1.3. Brazil By Technology, 2021 - 2030 (USD Million) 8.4.4.2. Mexico 8.4.4.2.1. Mexico By Product Type, 2021 - 2030 (USD Million) 8.4.4.2.3. Mexico By Technology, 2021 - 2030 (USD Million) 8.4.4.3. Rest of Latin America 8.4.4.3.1. Rest of the Latin America By Product Type, 2021 - 2030 (USD Million) 8.4.4.3.3. Rest of the Latin America By Technology, 2021 - 2030 (USD Million) 8.5. MEA 8.5.1. MEA By Product Type, 2021 - 2030 (USD Million) 8.5.3. MEA By Technology, 2021 - 2030 (USD Million) 9. Competitive Landscape 9.1 Ablative Solutions, Inc. 9.1.1. Company overview 9.1.2. Financial performance 9.1.3. ProductPortfolio Analysis 9.1.4. Business Strategy & Recent Development 9.2. Abbott Laboratories . 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Johnson & Johnson. 9.3.1. Company overview 9.3.2. Financial performance 9.3.3. Product Portfolio Analysis 9.3.4. Business Strategy & Recent Development 9.4. Cardiotonic Ltd. 9.4.1. Company overview 9.4.2. Financial performance 9.4.3. Product Portfolio Analysis 9.4.4. Business Strategy & Recent Development 9.5. Boston Scientific Corporation 9.5.1. Company overview 9.5.2. Financial performance 9.5.3. Product Portfolio Analysis 9.5.4. Business Strategy & Recent Development 9.6. Medtronic plc. 9.6.1. Company overview 9.6.2. Financial performance 9.6.3. Product Portfolio Analysis 9.6.4. Business Strategy & Recent Development 9.7. Mercator MedSystems, Inc. 9.7.1. Company overview 9.7.2. Financial performance 9.7.3. Product Portfolio Analysis 9.7.4. Business Strategy & Recent Development 9.8. ReCor Medical, Inc. 9.8.1. Company overview 9.8.2. Financial performance 9.8.3. Product Portfolio Analysis 9.8.4. Business Strategy & Recent Development 9.9. Renal Dynamics Limited. 9.9.1. Company overview 9.9.2. Financial performance 9.9.3. Product Portfolio Analysis 9.9.4. Business Strategy & Recent Development 9.10. Terumo corporation. 9.10.1. Company overview 9.10.2. Financial performance 9.10.3. Product Portfolio Analysis 9.10.4. Business Strategy & Recent Development List of Tables (65 Tables) TABLE 1. BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 2. FOR Radiofrequency, BY REGION, 2021-2030 (USD Million) TABLE 3. FOR Ultrasound, BY REGION, 2021-2030 (USD Million) TABLE 4. FOR Micro-Infusion, BY REGION, 2021-2030 (USD Million) TABLE 5. BY REGION, 2021-2030 (USD Million) TABLE 6. NORTH AMERICA BY COUNTRY, 2021-2030 (USD Million) TABLE 7. NORTH AMERICA BY Technology, 2021-2030 (USD Million) TABLE 8. NORTH AMERICA BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 9. EUROPE BY COUNTRY, 2021-2030 (USD Million) TABLE 10. EUROPE BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 11. ASIA-PACIFIC BY COUNTRY, 2021-2030 (USD Million) TABLE 12. ASIA-PACIFIC By Product Type, 2021-2030 (USD Million) TABLE 13. ASIA-PACIFIC BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 14. LAMEA BY COUNTRY, 2021-2030 (USD Million) TABLE 15. LAMEA BY TECHNOLOGY, 2021-2030 (USD Million) TABLE 16. Ablative Solutions, Inc: COMPANY SNAPSHOT TABLE 17. Ablative Solutions, Inc: OPERATING SEGMENTS TABLE 18. Abbott Laboratories: COMPANY SNAPSHOT TABLE 19. Abbott Laboratories: OPERATING SEGMENTS TABLE 20. Johnson & Johnson: COMPANY SNAPSHOT TABLE 21. Johnson & Johnson: OPERATING SEGMENTS TABLE 22. Cardiotonic Ltd: COMPANY SNAPSHOT TABLE 23. Cardiotonic Ltd: OPERATING SEGMENTS TABLE 24. Boston Scientific Corporation: COMPANY SNAPSHOT TABLE 25. Boston Scientific Corporation: OPERATING SEGMENTS TABLE 26. Medtronic plc: COMPANY SNAPSHOT TABLE 27. Medtronic plc: OPERATING SEGMENTS TABLE 28. Mercator MedSystems, Inc: COMPANY SNAPSHOT TABLE 29. Mercator MedSystems, Inc: OPERATING SEGMENTS TABLE 30. ReCor Medical, Inc: COMPANY SNAPSHOT TABLE 31. ReCor Medical, Inc: OPERATING SEGMENTS TABLE 32. Renal Dynamics Limited: COMPANY SNAPSHOT TABLE 33. Renal Dynamics Limited: OPERATING SEGMENTS TABLE 34. Terumo corporation: COMPANY SNAPSHOT TABLE 35. Terumo corporation: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries Figure 4 Research Methodology: Hypothesis Building Figure 5 Renal Denervation Market: Product-Based Estimation Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Renal Denervation, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Renal Denervation, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 By Technology, 2019 vs. 2025 (USD Million) Figure 12 Share, By Product Type, 2019 vs. 2025 Figure 13 Geographical Snapshot Figure 14 Radiofrequency to Witness Higher CAGR for Technology Segment during Forecast Period. Figure 15 Europe Accounted for the Largest Share, By Regional Basis, in 2019 Figure 16 Drivers, Restraints, Opportunities, and Challenges Figure 17 European Snapshot Figure 18 Asia Pacific Snapshot Figure 19 Vendor Dive: Evaluation Overview 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at Market size By bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size By Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Renal Denervation Market 4.2.1 Global Market, 2020 – 2028 (USD Million) 4.3 Regional Business Analysis 4.3.1 By Region, 2020 - 2028 (USD Million) 4.4 Technology Business Analysis 4.4.1 By Technology, 2020 - 2028 (USD Million) 4.5 Value Chain Analysis 4.6 Market Variable Analysis 4.6.1 Market Drivers Analysis 4.6.2 Market Restraints Analysis 4.7 Business Environment Analysis Tool 4.7.1 PEST analysis 4.7.2 Porter’s analysis 4.8 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. Technology Analysis 5.11.1. Trends in Technology (2014-2020) 5.11.2. Trends in Technology (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Country) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Renal Denervation Manufacturing Sites, Area Served, Product Type 6.3. Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Technology Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2020-2028) 7.3. Radiofrequency 7.3.1. Radiofrequency Market, 2020 - 2028 (USD Million) 7.4.Ultrasound 7.4.1. Ultrasound Market, 2020 - 2028 (USD Million) 7.5 Micro-Infusion 7.5.1 Micro-Infusion Market, 2020 - 2028 (USD Million) 8. Global Market: Regional Outlook 8.1 North America 8.1.1. North America By Product Type, 2020 - 2028 (USD Million) 8.1.4. North America By Technology, 2020 - 2028 (USD Million) 8.1.5. North America By Country, 2020 - 2028 (USD Million) 8.1.4.1. U.S. 8.1.4.1.1. U.S. By Product Type, 2020 - 2028 (USD Million) 8.1.4.2. Canada 8.1.4.2.1. Canada By Product Type, 2020 - 2028 (USD Million) 8.1.4.2.2. Canada By Region, 2020 - 2028 (USD Million) 8.1.4.2.3. Canada By Technology, 2020 - 2028 (USD Million) 8.2. Europe 8.2.1. Europe By Product Type, 2020 - 2028 (USD Million) 8.2.2. Europe By Technology, 2020 - 2028 (USD Million) 8.2.5. Europe By Country, 2020 - 2028 (USD Million) 8.2.4.1 U.K. 8.2.4.1.1. U.K. By Product Type, 2020 - 2028 (USD Million) 8.2.4.1.2. U.K. By Technology, 2020 - 2028 (USD Million) 8.2.4.1.3. U.K. By Region, 2020 - 2028 (USD Million) 8.2.4.2. Germany 8.2.4.2.1. Germany By Product Type, 2020 - 2028 (USD Million) 8.2.4.2.2. Germany By Technology, 2020 - 2028 (USD Million) 8.2.4.2.3. Germany By Region, 2020 - 2028 (USD Million) 8.2.4.3. France 8.2.4.3.1. France By Product Type, 2020 - 2028 (USD Million) 8.2.4.3.2. France By Region, 2020 - 2028 (USD Million) 8.2.4.3.3. France By Technology, 2020 - 2028 (USD Million) 8.2.4.4. Rest of Europe 8.2.4.4.1. Rest of Europe By Product Type, 2020 - 2028 (USD Million) 8.2.4.4.2. Rest of Europe By Region, 2020 - 2028 (USD Million) 8.2.4.4.3. Rest of By Technology, 2020 - 2028 (USD Million) 8.3. Asia Pacific 8.3.1. Asia Pacific By Product Type, 2020 - 2028 (USD Million) 8.3.2. Asia Pacific By Technology, 2020 - 2028 (USD Million) 8.3.5. Asia Pacific By Country, 2020 - 2028 (USD Million) 8.3.4.1. China 8.3.4.1.1. China By Product Type, 2020 - 2028 (USD Million) 8.3.4.1.2. China By Region, 2020 - 2028 (USD Million) 8.3.4.1.3. China By Technology, 2020 - 2028 (USD Million) 8.3.4.2. India 8.3.4.2.1. India By Product Type, 2020 - 2028 (USD Million) 8.3.4.2.2. India By Region, 2020 - 2028 (USD Million) 8.3.4.2.3. India By Technology, 2020 - 2028 (USD Million) 8.3.4.3. Japan 8.3.4.3.1. Japan By Product Type, 2020 - 2028 (USD Million) 8.3.4.3.3. Japan By Technology, 2020 - 2028 (USD Million) 8.3.4.4. South Korea 8.3.4.4.1. South Korea By Product Type, 2020 - 2028 (USD Million) 8.3.4.4.3. South Korea By Technology, 2020 - 2028 (USD Million) 8.3.4.5. Rest of ASIA PACIFIC 8.3.4.5.1. Rest of ASIA PACIFIC By Product Type, 2020 - 2028 (USD Million) 8.3.4.5.3. Rest of ASIA PACIFIC By Technology, 2020 - 2028 (USD Million) 8.4. Latin America 8.4.1. Latin America By Product Type, 2020 - 2028 (USD Million) 8.4.3. Latin America By Technology, 2020 - 2028 (USD Million) 8.4.4. Latin America By Country, 2020 - 2028 (USD Million) 8.4.4.1. Brazil 8.4.4.1.1. Brazil By Product Type, 2020 - 2028 (USD Million) 8.4.4.1.3. Brazil By Technology, 2020 - 2028 (USD Million) 8.4.4.2. Mexico 8.4.4.2.1. Mexico By Product Type, 2020 - 2028 (USD Million) 8.4.4.2.3. Mexico By Technology, 2020 - 2028 (USD Million) 8.4.4.3. Rest of Latin America 8.4.4.3.1. Rest of the Latin America By Product Type, 2020 - 2028 (USD Million) 8.4.4.3.3. Rest of the Latin America By Technology, 2020 - 2028 (USD Million) 8.5. MEA 8.5.1. MEA By Product Type, 2020 - 2028 (USD Million) 8.5.3. MEA By Technology, 2020 - 2028 (USD Million) 9. Competitive Landscape 9.1 Ablative Solutions, Inc. 9.1.1. Company overview 9.1.2. Financial performance 9.1.3. ProductPortfolio Analysis 9.1.4. Business Strategy & Recent Development 9.2. Abbott Laboratories . 10.2.1. Company overview 10.2.2. Financial performance 10.2.3. Product Portfolio Analysis 10.2.4. Business Strategy & Recent Development 10.3. Johnson & Johnson. 9.3.1. Company overview 9.3.2. Financial performance 9.3.3. Product Portfolio Analysis 9.3.4. Business Strategy & Recent Development 9.4. Cardiotonic Ltd. 9.4.1. Company overview 9.4.2. Financial performance 9.4.3. Product Portfolio Analysis 9.4.4. Business Strategy & Recent Development 9.5. Boston Scientific Corporation 9.5.1. Company overview 9.5.2. Financial performance 9.5.3. Product Portfolio Analysis 9.5.4. Business Strategy & Recent Development 9.6. Medtronic plc. 9.6.1. Company overview 9.6.2. Financial performance 9.6.3. Product Portfolio Analysis 9.6.4. Business Strategy & Recent Development 9.7. Mercator MedSystems, Inc. 9.7.1. Company overview 9.7.2. Financial performance 9.7.3. Product Portfolio Analysis 9.7.4. Business Strategy & Recent Development 9.8. ReCor Medical, Inc. 9.8.1. Company overview 9.8.2. Financial performance 9.8.3. Product Portfolio Analysis 9.8.4. Business Strategy & Recent Development 9.9. Renal Dynamics Limited. 9.9.1. Company overview 9.9.2. Financial performance 9.9.3. Product Portfolio Analysis 9.9.4. Business Strategy & Recent Development 9.10. Terumo corporation. 9.10.1. Company overview 9.10.2. Financial performance 9.10.3. Product Portfolio Analysis 9.10.4. Business Strategy & Recent Development List of Tables (65 Tables) TABLE 1. BY TECHNOLOGY, 2020-2028 (USD Million) TABLE 2. FOR Radiofrequency, BY REGION, 2020-2028 (USD Million) TABLE 3. FOR Ultrasound, BY REGION, 2020-2028 (USD Million) TABLE 4. FOR Micro-Infusion, BY REGION, 2020-2028 (USD Million) TABLE 5. BY REGION, 2020-2028 (USD Million) TABLE 6. NORTH AMERICA BY COUNTRY, 2020-2028 (USD Million) TABLE 7. NORTH AMERICA BY Technology, 2020-2028 (USD Million) TABLE 8. NORTH AMERICA BY TECHNOLOGY, 2020-2028 (USD Million) TABLE 9. EUROPE BY COUNTRY, 2020-2028 (USD Million) TABLE 10. EUROPE BY TECHNOLOGY, 2020-2028 (USD Million) TABLE 11. ASIA-PACIFIC BY COUNTRY, 2020-2028 (USD Million) TABLE 12. ASIA-PACIFIC By Product Type, 2020-2028 (USD Million) TABLE 13. ASIA-PACIFIC BY TECHNOLOGY, 2020-2028 (USD Million) TABLE 14. LAMEA BY COUNTRY, 2020-2028 (USD Million) TABLE 15. LAMEA BY TECHNOLOGY, 2020-2028 (USD Million) TABLE 16. Ablative Solutions, Inc: COMPANY SNAPSHOT TABLE 17. Ablative Solutions, Inc: OPERATING SEGMENTS TABLE 18. Abbott Laboratories: COMPANY SNAPSHOT TABLE 19. Abbott Laboratories: OPERATING SEGMENTS TABLE 20. Johnson & Johnson: COMPANY SNAPSHOT TABLE 21. Johnson & Johnson: OPERATING SEGMENTS TABLE 22. Cardiotonic Ltd: COMPANY SNAPSHOT TABLE 23. Cardiotonic Ltd: OPERATING SEGMENTS TABLE 24. Boston Scientific Corporation: COMPANY SNAPSHOT TABLE 25. Boston Scientific Corporation: OPERATING SEGMENTS TABLE 26. Medtronic plc: COMPANY SNAPSHOT TABLE 27. Medtronic plc: OPERATING SEGMENTS TABLE 28. Mercator MedSystems, Inc: COMPANY SNAPSHOT TABLE 29. Mercator MedSystems, Inc: OPERATING SEGMENTS TABLE 30. ReCor Medical, Inc: COMPANY SNAPSHOT TABLE 31. ReCor Medical, Inc: OPERATING SEGMENTS TABLE 32. Renal Dynamics Limited: COMPANY SNAPSHOT TABLE 33. Renal Dynamics Limited: OPERATING SEGMENTS TABLE 34. Terumo corporation: COMPANY SNAPSHOT TABLE 35. Terumo corporation: OPERATING SEGMENTS List of Figures (20 Figures) Figure 1 Research Methodology Steps Figure 2 Research Design Figure 3 Breakdown of Primaries Figure 4 Research Methodology: Hypothesis Building Figure 5 Renal Denervation Market: Product-Based Estimation Figure 6 Top 10 Companies with Highest No. Of Patent in Last 9 Years Figure 7 No. Of Patents Granted Per Year, 2019–2020 Figure 8 Import Data for Renal Denervation, By Country, 2016–2020 (USD Thousand) Figure 9 Export Data for Renal Denervation, By Country, 2016–2020 (USD Thousand) Figure 10 Data Triangulation Methodology Figure 11 By Technology, 2019 vs. 2025 (USD Million) Figure 12 Share, By Product Type, 2019 vs. 2025 Figure 13 Geographical Snapshot Figure 14 Radiofrequency to Witness Higher CAGR for Technology Segment during Forecast Period. Figure 15 Europe Accounted for the Largest Share, By Regional Basis, in 2019 Figure 16 Drivers, Restraints, Opportunities, and Challenges Figure 17 European Snapshot Figure 18 Asia Pacific Snapshot Figure 19 Vendor Dive: Evaluation Overview